Literature DB >> 24246313

Population pharmacokinetics meets microdialysis: benefits, pitfalls and necessities of new analysis approaches for human microdialysis data.

André Schaeftlein1, Iris K Minichmayr1, Charlotte Kloft2.   

Abstract

Pharmacokinetic (PK) data originating from human microdialysis studies have by now most commonly been analysed using noncompartmental analysis or the standard two-stage population approach. During the last decades, additional modelling strategies for PK data have been developed, which also seem apt for the analysis of microdialysis data. The present opinion article gives an overview of the three approaches of nonlinear mixed-effects (NLME) modelling, physiologically-based pharmacokinetic (PBPK) modelling and a combined population PBPK modelling approach (PPBPK) as well as their application within the field of microdialysis in humans. Potential benefits and pitfalls of the different approaches will be outlined and exemplified, complemented by modelling prerequisites to be met on the part of principal investigators, bioanalysts and documentalists involved in a microdialysis study. In summary, the combination of microdialysis as the method of choice for measuring unbound drug concentrations in peripheral tissues and the presented modelling strategies seems a promising way to enhance the understanding of drug disposition at the target site of drugs and might thus contribute to a more rational use of medicines.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Data analysis; Humans; Microdialysis; NLME; PBPK; Population PBPK

Mesh:

Substances:

Year:  2013        PMID: 24246313     DOI: 10.1016/j.ejps.2013.11.004

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  7 in total

1.  A population pharmacokinetic model of intravenous telavancin in healthy individuals to assess tissue exposure.

Authors:  Sami Ullah; Peter Matzneller; Markus Zeitlinger; Uwe Fuhr; Max Taubert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-05-06       Impact factor: 3.000

Review 2.  Utility of Microdialysis in Infectious Disease Drug Development and Dose Optimization.

Authors:  Amelia N Deitchman; M Tobias Heinrichs; Vipada Khaowroongrueng; Satyawan B Jadhav; Hartmut Derendorf
Journal:  AAPS J       Date:  2016-12-09       Impact factor: 4.009

3.  Microdialysis of Drug and Drug Metabolite: a Comprehensive In Vitro Analysis for Voriconazole and Voriconazole N-oxide.

Authors:  Josefine Schulz; Robin Michelet; Markus Zeitlinger; Gerd Mikus; Charlotte Kloft
Journal:  Pharm Res       Date:  2022-09-28       Impact factor: 4.580

4.  Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients.

Authors:  Iris K Minichmayr; André Schaeftlein; Joseph L Kuti; Markus Zeitlinger; Charlotte Kloft
Journal:  Clin Pharmacokinet       Date:  2017-06       Impact factor: 6.447

5.  Translational Pharmacometric Evaluation of Typical Antibiotic Broad-Spectrum Combination Therapies Against Staphylococcus Aureus Exploiting In Vitro Information.

Authors:  S G Wicha; W Huisinga; C Kloft
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-07-13

6.  Measurement of soft tissue drug concentrations in morbidly obese and non-obese patients - A prospective, parallel group, open-labeled, controlled, phase IV, single center clinical trial.

Authors:  P Simon; D Petroff; C Dorn; L Ehmann; C Kloft; C Prettin; A Dietrich; M Zeitlinger; F Kees; H Wrigge
Journal:  Contemp Clin Trials Commun       Date:  2019-05-10

7.  Monitoring vigabatrin in head injury patients by cerebral microdialysis: obtaining pharmacokinetic measurements in a neurocritical care setting.

Authors:  Richard J Shannon; Ivan Timofeev; Jürgens Nortje; Peter J Hutchinson; Keri L H Carpenter
Journal:  Br J Clin Pharmacol       Date:  2014-11       Impact factor: 4.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.